Teva and Sanofi Current New Constructive Section 2b Research Outcomes at ECCO 2025 Reinforcing Greatest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Illness
This part is Partnership Content material equippedThe content material on this part is equipped by GlobeNewswire for the needs of...